公开(公告)号：US11304992B2

公开(公告)日：2022-04-19

申请号：US16721357

申请日：2019-12-19

Applicant: MannKind Corporation

Inventor： Donald Costello ,  Peter Richardson ,  Robert A. Baughman ,  Mark T. Marino

IPC: A61K31/706 ,  A61K9/00 ,  A61K38/26 ,  A61K45/06 ,  A61K31/4965 ,  A61K47/26

Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.

公开(公告)号：US20210244897A1

公开(公告)日：2021-08-12

申请号：US17244730

申请日：2021-04-29

Applicant: MannKind Corporation

Inventor： Chad C. Smutney ,  Benoit Adamo ,  John M. Polidoro ,  P. Spencer Kinsey ,  Dennis Overfield ,  Carl R. Sahi ,  Christine Billings ,  Mark T. Marino

IPC: A61M15/00 ,  A61K38/28 ,  A61K9/00

Abstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of endocrine disease, for example, diabetes and/or obesity.

公开(公告)号：US20170304404A1

公开(公告)日：2017-10-26

申请号：US15640835

申请日：2017-07-03

Applicant: MannKind Corporation

Inventor： Donald Costello ,  Peter Richardson ,  Robert A. Baughman ,  Mark T. Marino

IPC: A61K38/26 ,  A61K45/06 ,  A61K31/4965 ,  A61K47/26 ,  A61K9/00

CPC classification number: A61K38/26 ,  A61K9/0075 ,  A61K31/4965 ,  A61K45/06 ,  A61K47/26 ,  A61K2300/00

Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.

公开(公告)号：US20160287820A1

公开(公告)日：2016-10-06

申请号：US15182503

申请日：2016-06-14

Applicant: MannKind Corporation

Inventor： Chad C. Smutney ,  Beniot Adamo ,  John M. Polidoro ,  P. Spencer Kinsey ,  Dennis Overfield ,  Carl R. Sahi ,  Christine Billings ,  Mark T. Marino

IPC: A61M15/00 ,  A61K38/28 ,  A61K9/00

CPC classification number: A61M15/0091 ,  A61K9/0075 ,  A61K38/28 ,  A61M15/0021 ,  A61M15/0028 ,  A61M15/0043 ,  A61M2202/064 ,  A61M2205/6081

Abstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of endocrine disease, for example, diabetes and/or obesity.

Abstract translation: 公开了一种肺部药物递送系统，包括呼吸动力的干粉吸入器和用于递送干粉制剂的药筒。 吸入器和药筒可以配备药物递送制剂，其包含例如二酮哌嗪和活性成分，包括肽和蛋白质如胰岛素和胰高血糖素样肽1，用于治疗内分泌疾病，例如糖尿病和 /或肥胖。